Essential Facts About Regeneron Pharmaceuticals

Large-cap Healthcare company Regeneron Pharmaceuticals has logged a -7.9% change today on a trading volume of 407,266. The average volume for the stock is 649,835.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Based in Tarrytown, United States the company has 10,715 full time employees and a market cap of $73,033,523,200.

The company is now trading -12.53% away from its average analyst target price of $776.39 per share. The 23 analysts following the stock have set target prices ranging from $575 to $1025, and on average give Regeneron Pharmaceuticals a rating of buy.

Date Reported Revenue ($ MM) Cost of Revenue ($ MM) Gross Margins (%) YoY Growth (%)
2021-12-31 16,072 2,438 84.83 -2.29
2020-12-31 8,497 1,120 86.82 -3.59
2019-12-31 7,863 782 90.05 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.